Investing.com -- Shares of Allurion Technologies (NYSE: ALUR) skyrocketed by 350% following the company's announcement of its plans to initiate a clinical study aimed at optimizing muscle mass during ...
Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average weight loss of 22% over 36 weeks. This is in contrast to a 2% increase observed ...
(Reuters) - U.S. stock index futures dipped on Friday, as uncertainty about President Donald Trump's trade policies prevailed, while investors also awaited data and corporate earnings reports that ...